Massive study aims to unravel mysteries of blood clots and vessel disease
NCT ID NCT06552767
First seen Jun 25, 2026 · Last updated Sep 11, 2026 · Updated 12 times
Summary
This study aims to learn more about how diseases related to blood clots, the immune system, and blood vessels start and change over time. Researchers will enroll up to 1,000 people aged 5 and older, including those with these conditions, their healthy relatives, and healthy volunteers. Participants will undergo various tests and procedures, such as blood tests, imaging scans, and heart function tests, with optional follow-up for up to 7.5 years.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 1,000 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Nov 2024
- Expected to finish
-
Jan 2034
An estimate. End dates often move.
- Lead sponsor
-
A government research agency
The lead sponsor is the US National Institutes of Health.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Participants with relevant immune, inflammation, thrombotic and/or vascular diseases and their relatives Healthy volunteers
- Ages
-
5 to 100 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
* INCLUSION CRITERIA: In order to be eligible to participate in this study, an individual must meet all of the following criteria: * Age \>= 5 years at the time of consent * Ability of subject or Legally Authorized Representative (LAR) as applicable to understand and the willingness to sign a written informed consent document In addition, the following cohort-specific inclusion criteria apply: Affected Subjects: -Known or possible thrombotic, immune, or vascular disorder after review of the subject s medical records and/or discussion of medical history Relatives of Affected Subjects: -Being a relative of an affected subject Unrelated Healthy Controls: -In good general health as evidenced by medical history EXCLUSION CRITERIA: An individual who meets any of the following criteria will be excluded from participation in this study: -Any condition that in the opinion of the Investigator would warrant exclusion Unrelated Healthy Controls: * Unrelated healthy volunteers who decline to have blood drawn and/or tissue studies or who do not consent to have samples stored for future research * Cognitively impaired individuals
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cardiovascular diseases are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a nurse and a neighbor help tame chronic disease?
- Two eggs a day put to the test for heart health
- A soft patch that watches your heart beat in real time
- Could a quieter, automated blood pressure check help more people control hypertension?
- Can a Once-Daily form of tacrolimus spare liver transplant patients from side effects?
- Inhaled drug aims to ease dangerous lung blood pressure in scarred lungs